Homocysteine and cognitive impairment in Parkinson's disease;Homocisteína y deterioro cognitivo en la enfermedad de Parkinson

Revista de Neurologia

Volumn 50, Issue 3, 2010, Pages 145-151

  Martín Fernández, José Javier ^a,b   Carles Díes, Rafael ^a   Cañizares, Francisco ^a   Parra, Soledad ^a   Avilés, Francisco ^a   Villegas, Irene ^a   Morsi Hassan, Ossama ^a   Fernández Barreiro, Andrés ^a   Herrero, M Trinidad ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Cognitive impairment; Folic acid; Homocysteine; Levodopa; Parkinson

Indexed keywords

CYANOCOBALAMIN; ENTACAPONE; FOLIC ACID; HOMOCYSTEINE; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; COGNITION; COGNITIVE DEFECT; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PSYCHOLOGIC ASSESSMENT; SEX DIFFERENCE; TREATMENT DURATION; VITAMIN BLOOD LEVEL;

EID: 76749113055     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5003.2009276     Document Type: Article

References (49)

1. McCully KS. Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr 2007; 86: 1563-8.
2. Herrmann W, Herrmann M, Obeid R. Hyperhomocysteinaemia: a critical review of old and new aspects. Curr Drug Metab 2007; 8: 17-31.
3. García-Pinilla JM, Espinosa-Caliani S, Gómez-Doblas JJ, Jiménez-Navarro M, Gaitán MJ, Muñoz-Morán E, et al. Influence of high homocysteine and low folate plasmatic levels in medium-term prognosis after acute coronary syndromes. Int J Cardiol 2007; 118: 220-6.
4. Ribacoba R, Menéndez M, Virgili JR, Jiménez G, Buerta C, Álvarez MV, et al. Hiperhomocisteinemia y polimorfismo C677T del gen MTHFR como factores de riesgo de enfermedad cardiovascular y deterioro cognitivo en la enfermedad de Parkinson. Revista Española de Trastornos del Movimiento 2007; 6: 14-20.
5. Rogers JD, Sánchez-Saffon A, Frol AB, Díaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003; 60: 59-64.
6. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 1997; 94: 5923-8.
7. Lee ES, Chen H, Soliman KF, Charlton CG. Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 2005; 26: 361-71.
8. White AR, Huang X, Jobling MF, Barrow CJ, Beyreuther K, Masters CL, et al. Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. J Neurochem 2001; 76: 1509-20.
9. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002; 80: 101-10.
10. Krumdieck CL, Prince CW. Mechanisms of Homocysteine Toxicity on Connective Tissues: Implications for the Morbidity of Aging. J Nutr 2000; 130 (Suppl 2): S365-8.
11. Schafer JH, Glass TA, Bolla KI, Mintz M, Jedlicka AE, Schwartz BS. Homocysteine and cognitive function in a population-based study of older adults. J Am Geriatr Soc 2005; 53: 381-8.
12. 12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am J Med 2005; 118: 161-7.
13. Ozer F, Meral H, Hanoglu L, Aydemir T, Yilsen M, Cetin S, et al. Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurol Res 2006; 28: 853-8.
14. Clarke R, Birks J, Nexo E, Ueland PM, Schneede J, Scott J, et al. Low vitamin B12 status and risk of cognitive decline in older adults. Am J Clin Nutr 2007; 86: 1384-91.
15. Kim J, Park MH, Kim E, Han C, Jo SA, Jo I. Plasma homocysteine is associated with the risk of mild cognitive impairment in an elderly Korean population. J Nutr 2007; 137: 2093-7.
16. Haan MN, Miller JW, Aiello AE, Whitmer RA, Jagust WJ, Mungas DM, et al. Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. Am J Clin Nutr 2007; 85: 511-7.
17. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-83.
18. Zoccolella S, Lamberti P, Iliceto G, Diroma C, Armenise E, Defazio G, et al. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clin Chem Lab Med 2005; 43: 1107-10.
19. O'Suilleabhain PE, Sung V, Hernández C, Lacritz L, Dewey RB, Bottiglieri T, et al. Elevated plasma homocysteine level in patients with Parkinson disease. Motor, affective, and cognitive associations. Arch Neurol 2004; 61: 865-8.
20. Tolmunen T, Hintikka J, Voutilainen S, Ruusunen A, Alfthan G, Nyyssönen K, et al. Association between depressive symptoms and serum concentrations of homocysteine in men: a population study. Am J Clin Nutr 2004; 80: 1574-8.
21. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MWP, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000; 69: 228-32.
22. Soumaré A, Elbaz, A, Ducros V, Tavernier B, Alpérovitch A, Tzourio C. Cross-sectional association between homocysteine and motor function in the elderly. Neurology 2006; 67: 985-90.
23. Irizarry MC, Gurol ME, Raju S, Díaz-Arrastia R, Locascio JJ, Tennis M, et al. Association of homocysteine with plasma amyloid β protein in aging and neurodegenerative disease. Neurology 2005; 65: 1402-8.
24. Lerner V, Miodownik CH, Kaptsan A, Vishne T, Sela BA, Levine J. High serum homocysteine levels in young male schizophrenic and schizoaffective patients with tardive parkinsonism and/or tardive dyskinesia. J Clin Psychiatry 2005; 66: 1558-63.
25. Zoccolella S, Lamberti P, Iliceto G, Dell'Aquila C, Diroma C, Fraddosio A, et al. Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias. Clin Chem Lab Med 2006; 44: 863-6.
26. Agnati LF, Ferre S, Genedani S, Leo G, Guidolin, D, Filaferro M, et al. Allosteric modulation of dopamine D-2 receptors by homocysteine. J Proteome Res 2006; 5: 3077-83.
27. Hoey L, McNulty H, Askin N, Dunne A, Ward M, Pentieva K, et al. Effect of a voluntary food fortification policy on folate, related B vitamin status, and homocysteine in healthy adults. Am J Clin Nutr 2007; 86: 1405-13.
28. Postuma RB, Espay AJ, Zadikoff C, Suchowersky O, Martin WR, Lafontaine AL, et al. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 2006; 66: 1941-3.
29. Zappia M, Nicoletti A, Muñoz-S. D, Tapia-Núñez J. Reconsideraciones en el tratamiento de la enfermedad de Parkinson con levodopa: evidencias farmacodinámicas. Rev Neurol 2009; 49: 33-40.
30. Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, De Mari M, et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord 2005; 20: 69-72.
31. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003; 60: 1125-9.
32. Ostrem JL, Kang GA, Subramanian I, Guarnieri M, Hubble J, Rabinowicz AL, et al. The effect of entacapone on homocysteine levels in Parkinson disease. Neurology 2005; 64: 1482.
33. Religa D, Czyzewski K, Styczynska M, Peplonska B, Lokk J, Chodakowska-Zebrowska M, et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci Lett 2006; 404: 56-60.
34. 12 and folate levels in Parkinson's disease patients. Eur Neurol 2007; 58: 96-9.
35. Nissinen E, Nissinen H, Larjonmaa H, Väänänen A, Helkamaa T, Reenilä I, et al. The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. J Neural Transm 2005; 112: 1213-21.
36. Hassin-Baer S, Cohen O, Vakil E, Sela BA, Nitsan Z, Schwartz R, et al. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin Neuropharmacol 2006; 29: 305-11.
37. Wang X, Oin X, Demirtas H, Li J, Mao G, Huo Y, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007; 369: 1876-82.
38. Luchsinger JA, Tang MX, Miller J, Green R, Mayeux R. Relation of higher folate intake to lower risk of Alzheimer disease in the elderly. Arch Neurol 2007; 64: 86-92.
39. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-18.
40. Zesiewicz TA, Wecker L, Sullivan KL, Merlin LR, Hauser RA. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. Clin Neuropharmacol 2006; 29: 106-11.
41. Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord 2005; 11: 253-6.
42. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 2005; 82: 636-43.
43. Cacho J, García-García R, Arcaya J, Vicente JL, Lantada N. Una propuesta de aplicación y puntuación del test del reloj en la enfermedad de Alzheimer. Rev Neurol 1999; 28: 648-55.
44. Peña-Casanova J. Programa integrado de exploración neuropsicológica. Test Barcelona (manual). Barcelona: Masson; 1990.
45. Peña-Casanova J. Programa integrado de exploración neuropsicológica. Test Barcelona. Barcelona: Masson; 1991.
46. Blesa R, Pujol M, Aguilar M, Santacruz P, Bertrán-Serra I, Hernández G, et al. Clinical validity of the 'minimental state' for Spanish speaking communities. Neuropsychologia 2001; 39: 1150-7.
47. Cummings JL, Mega M, Gray K, Rosenberg-Thopmson S, Carusi DA, Gombein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
48. Chervase DG, Tormo-Díaz MJ, Antúnez-Almagro C, García-Santos JM, Carles-Díes R, Fortuna L, et al. Valores normativos del test Minimental State Examination (MMSE) para la evaluación de la función cognitiva en población mayor de 64 años del municipio de Murcia: estudio Ariadna. Bol Epidemiol Murcia 2008; 29: 711.
49. Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol 2005; 252: 753-64.